Federal health regulators will soon face their next controversial vaccine decision: whether to authorize Pfizer's vaccine for children younger than 5, despite ongoing questions around dosing and effectiveness.
Why it matters: Once again, the pandemic is forcing health officials to choose between unconventional vaccine approval methods and the human costs of abiding by more traditional — yet time-consuming — regulatory processes.
